Patent Publication Number: US-6037142-A

Title: Antisense inhibition of SMAD2 expression

Description:
FIELD OF THE INVENTION 
     The present invention provides compositions and methods for modulating the expression of Smad2. In particular, this invention relates to antisense compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding human Smad2. Such oligonucleotides have been shown to modulate the expression of Smad2. 
     BACKGROUND OF THE INVENTION 
     The transforming growth factor-beta (TGF-β) superfamily of cytokines regulate a diverse array of physiologic functions including cell proliferation and growth, cell migration, differentiation, development and apoptosis. This large family includes the TGF-βs, activins, and bone-morphogenic proteins (BMPs) and each subgroup initiates a unique signaling cascade activated by ligand-induced serine/threonine kinase receptor complex formation (Wrana, Miner. Electrolyte Metab., 1998, 24, 120-130). These complexes, once formed, recruit and phosphorylate members of a family of cytosolic proteins, known as Smads. Smads exist as monomers in unstimulated cells but homo- or heterodimerize and translocate to the nucleus activating target gene transcription upon ligand binding. Smads, therefore, connect the pathway of TGF-β signaling from the cell membrane to the nucleus. 
     To date, nine vertebrate Smads have been identified and these have been divided into subgroups based on their functional role in various pathways. Smad1, 5, and MADH6, which is 80% homologous to Smad1, all mediate signal transduction from BMPs while Smad2 and 3 mediate signal transduction from TGF-βs and activins. Collectively, these Smads are known as the pathway-restricted Smads and can form homo or heterodimers. Smad4 has been shown to be a shared hetero-oligomerization partner to the pathway-restricted Smads and is known as the common mediator. The last two members of the family, Smad6 and 7, act to inhibit the Smad signaling cascades often by forming unproductive dimers with other Smads and are therefore classified as antagonistic Smads (Heldin et al., Nature, 1997, 390, 465-471; Kretzschmar and Massague, Curr. Opin. Genet. Dev., 1998, 8, 103-111). 
     Smad2 (also known as MADH2, MADR2, hMAD2 and JV18-1) is a member of a subgroup of Smad family transcription factors which are regulated by TGF-β and activins. Upon ligand binding Smad2 becomes phosphorylated and associates with Smad3. This complex then associates with Smad4 and translocates to the nucleus where it effects transcription of target genes. It has been demonstrated that the phosphorylation of Smad2 is necessary for the association with Smad4 (Souchelnytskyi et al., J. Biol. Chem., 1997, 272, 28107-28115) and that Smad2 and Smad4 interact with CREB binding protein, an essential component of the mammalian transcription apparatus (Topper et al., Proc. Natl. Acad. Sci. U.S.A., 1998, 95, 9506-9511). 
     The Smad2 gene is located on chromosome 18q21, a region that frequently undergoes allelic loss in many cancers. A missense somatic mutation and a 9-bp in-frame deletion were detected in the highly conserved region of JV18-1 among 57 lung cancer specimens taken directly from patients (Uchida et al., Cancer Res., 1996, 56, 5583-5585). In addition, missense and nonsense mutations of the Smad2 gene have also been found in 6-17% of colorectal carcinoma cell lines and primary tumors (Eppert et al., Cell, 1996, 86, 543-552). 
     In normal cells, Smad2 acts to transmit signals from TGF-β and the activins. It has also been shown to mediate cross-talk between receptor tyrosine kinase pathways and receptor serine/threonine kinase pathways by acting as a positive effector in the EGF and HGF signaling cascades (de Caestecker et al., Genes Dev., 1998, 12, 1587-1592). 
     Currently, there are no known therapeutic agents which effectively inhibit the synthesis of Smad2 and to date, strategies aimed at inhibiting Smad2 function have involved the use of dominant-negative mutants of Smad2, gene knock-outs in mice and antisense oligonucleotides designed against Smad2. 
     Studies of mice lacking the Smad2 gene showed that Smad2 is necessary for embryonic mesoderm formation and the establishment of anterior-posterior polarity (Waldrip et al., Cell, 1998, 92, 797-808). Analysis of mice lacking one copy of the gene found that developmental changes depended on the amount of Smad2 activity and that a defective phenotype was apparent when both of the Smad2 genes are inactivated (Nomura and Li, Nature, 1998, 393, 786-790). 
     Antisense oligonucleotides designed against Smad2 were used in studies of lung morphogenesis to show that Smad2 negatively regulates lung organogenesis. In these studies, it was demonstrated that treatment of embryonic mouse lung cultures with Smad2 antisense oligonucleotides resulted in increased lung branching morphogenesis (Zhao et al., Dev. Biol., 1998, 194, 182-195). 
     In light of the limited strategies available for targeting Smad2 function, there remains a long felt need for additional agents capable of effectively inhibiting Smad2. Therefore, antisense oligonucleotides may provide a promising new pharmaceutical tool for the effective and specific modulation of Smad2 expression. 
     SUMMARY OF THE INVENTION 
     The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding Smad2, and which modulate the expression of Smad2. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided. Further provided are methods of modulating the expression of Smad2 in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention. Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of Smad2 by administering a therapeutically or prophylactically effective amount of one or more of the antisense compounds or compositions of the invention. 
     DETAILED DESCRIPTION OF THE INVENTION 
     The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in modulating the function of nucleic acid molecules encoding Smad2, ultimately modulating the amount of Smad2 produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding Smad2. As used herein, the terms &#34;target nucleic acid&#34; and &#34;nucleic acid encoding Smad2&#34; encompass DNA encoding Smad2, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as &#34;antisense&#34;. The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of Smad2. In the context of the present invention, &#34;modulation&#34; means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target. 
     It is preferred to target specific nucleic acids for antisense. &#34;Targeting&#34; an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding Smad2. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5&#39;-AUG (in transcribed mRNA molecules; 5&#39;-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the &#34;AUG codon,&#34; the &#34;start codon&#34; or the &#34;AUG start codon&#34;. A minority of genes have a translation initiation codon having the RNA sequence 5&#39;-GUG, 5&#39;-UUG or 5&#39;-CUG, and 5&#39;-AUA, 5&#39;-ACG and 5&#39;-CUG have been shown to function in vivo. Thus, the terms &#34;translation initiation codon&#34; and &#34;start codon&#34; can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, &#34;start codon&#34; and &#34;translation initiation codon&#34; refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding Smad2, regardless of the sequence(s) of such codons. 
     It is also known in the art that a translation termination codon (or &#34;stop codon&#34;) of a gene may have one of three sequences, i.e., 5&#39;-UAA, 5&#39;-UAG and 5&#39;-UGA (the corresponding DNA sequences are 5&#39;-TAA, 5&#39;-TAG and 5&#39;-TGA, respectively). The terms &#34;start codon region&#34; and &#34;translation initiation codon region&#34; refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5&#39; or 3&#39;) from a translation initiation codon. Similarly, the terms &#34;stop codon region&#34; and &#34;translation termination codon region&#34; refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5&#39; or 3&#39;) from a translation termination codon. 
     The open reading frame (ORF) or &#34;coding region,&#34; which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5&#39; untranslated region (5&#39;UTR), known in the art to refer to the portion of an mRNA in the 5&#39; direction from the translation initiation codon, and thus including nucleotides between the 5&#39; cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3&#39; untranslated region (3&#39;UTR), known in the art to refer to the portion of an mRNA in the 3&#39; direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3&#39; end of an mRNA or corresponding nucleotides on the gene. The 5&#39; cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5&#39;-most residue of the mRNA via a 5&#39;--5&#39; triphosphate linkage. The 5&#39; cap region of an mRNA is considered to include the 5&#39; cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5&#39; cap region may also be a preferred target region. 
     Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as &#34;introns,&#34; which are excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as &#34;exons&#34; and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA. 
     Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect. 
     In the context of this invention, &#34;hybridization&#34; means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. &#34;Complementary,&#34; as used herein, refers to the capacity for precise pairing between two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, &#34;specifically hybridizable&#34; and &#34;complementary&#34; are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed. 
     Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use. 
     The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term &#34;oligonucleotide&#34; refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases. 
     While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases. Particularly preferred are antisense oligonucleotides comprising from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2&#39;, 3&#39; or 5&#39; hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3&#39; to 5&#39; phosphodiester linkage. 
     Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides. 
     Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotri-esters, methyl and other alkyl phosphonates including 3&#39;-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3&#39;-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3&#39;-5&#39; linkages, 2&#39;-5&#39; linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3&#39;-5&#39; to 5&#39;-3&#39; or 2&#39;-5&#39; to 5&#39;-2&#39;. Various salts, mixed salts and free acid forms are also included. 
     Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S. Pat. Nos.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are commonly owned with this application, and each of which is herein incorporated by reference. 
     Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH 2  component parts. 
     Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference. 
     In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., Science, 1991, 254, 1497-1500. 
     Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular --CH 2  --NH--O--CH 2  --, --CH 2  --N(CH 3 )--O--CH 2  -- [known as a methylene (methylimino) or MMI backbone], --CH 2  --O--N (CH 3 )--CH 2  --, --CH 2  --N(CH 3 )--N(CH 3 )--CH 2  -- and --O--N(CH 3 )--CH 2  --CH 2  -- [wherein the native phosphodiester backbone is represented as --O--P--O--CH 2  --] of the above referenced U.S. Pat. No. 5,489,677, and the amide backbones of the above referenced U.S. Pat. No. 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. Pat. No. 5,034,506. 
     Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2&#39; position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C 1  to C 10  alkyl or C 2  to C 10  alkenyl and alkynyl. Particularly preferred are O[(CH 2 ) n  O] m  CH 3 , O(CH 2 ) n  OCH 3 , O(CH 2 ) n  NH 2 , O(CH 2 ) n  CH 3 , O(CH 2 ) n  ONH 2 , and O(CH 2 ) n  ON [(CH 2 ) n  CH 3 )] 2 , where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2&#39; position: C 1  to C 10  lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, Cl, Br, CN, CF 3 , OCF 3 , SOCH 3 , SO 2  CH 3 , ONO 2 , NO 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2&#39;-methoxyethoxy (2&#39;-O--CH 2  CH 2  OCH 3 , also known as 2&#39;-O--(2-methoxyethyl) or 2&#39;-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2&#39;-dimethylaminooxyethoxy, i.e., a O(CH 2 ) 2  ON(CH 3 ) 2  group, also known as 2&#39;-DMAOE, as described in examples hereinbelow. 
     Other preferred modifications include 2&#39;-methoxy (2&#39;--O--CH 3 ), 2&#39;-aminopropoxy (2&#39;-OCH 2  CH 2  CH 2  NH 2 ) and 2&#39;-fluoro (2&#39;-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3&#39; position of the sugar on the 3&#39; terminal nucleotide or in 2&#39;-5&#39; linked oligonucleotides and the 5&#39; position of 5&#39; terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat. Nos.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety. 
     Oligonucleotides may also include nucleobase (often referred to in the art simply as &#34;base&#34;) modifications or substitutions. As used herein, &#34;unmodified&#34; or &#34;natural&#34; nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859, Kroschwitz, J. I., ed. John Wiley &amp; Sons, 1990, those disclosed by Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., Chapter 15, Antisense Research and Applications, pages 289-302, Crooke, S. T. and Lebleu, B. ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when combined with 2&#39;-O-methoxyethyl sugar modifications. 
     Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. Pat. No. 3,687,808, as well as U.S. Pat. Nos.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and U.S. Pat. No. 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference. 
     Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., EMBO J., 1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330; Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res., 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides &amp; Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol. Exp. Ther., 1996, 277, 923-937. 
     Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S. Pat. Nos.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference. 
     It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. &#34;Chimeric&#34; antisense compounds or &#34;chimeras,&#34; in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art. 
     Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat. Nos.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety. 
     The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives. 
     The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S. Pat. Nos.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556; 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference. 
     The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. 
     The term &#34;prodrug&#34; indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published Dec. 9, 1993 or in WO 94/26764 to Imbach et al. 
     The term &#34;pharmaceutically acceptable salts&#34; refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. 
     Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N&#39;-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., &#34;Pharmaceutical Salts,&#34; J. of Pharma Sci., 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a &#34;pharmaceutical addition salt&#34; includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible. 
     For oligonucleotides, preferred examples of pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine. 
     The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of Smad2 is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example. 
     The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding Smad2, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding Smad2 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of Smad2 in a sample may also be prepared. 
     The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2&#39;-O-methoxyethyl modification are believed to be particularly useful for oral administration. 
     Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful. 
     Compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable. 
     Compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients. 
     Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids. 
     The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product. 
     The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers. 
     In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention. 
     Emulsions 
     The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in Remington&#39;s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 301). Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion. 
     Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). 
     Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285). 
     Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate. 
     A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). 
     Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase. 
     Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin. 
     The application of emulsion formulations via dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions. 
     In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: Controlled Release of Drugs: Polymers and Aggregate Systems, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in Remington&#39;s Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1985, p. 271). 
     The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously. 
     Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and triglycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone oil. 
     Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385-1390; Ritschel, Meth. Find. Exp. Clin. Pharmacol., 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., Pharmaceutical Research, 1994, 11, 1385; Ho et al., J. Pharm. Sci., 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration. 
     Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories--surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p. 92). Each of these classes has been discussed above. 
     Liposomes 
     There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term &#34;liposomel&#34; means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. 
     Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Noncationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages in vivo. 
     In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores. 
     Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes. 
     Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act. 
     Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin. 
     Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis. 
     Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., Biochem. Biophys. Res. Commun., 1987, 147, 980-985). 
     Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., Journal of Controlled Release, 1992, 19, 269-274). 
     One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol. 
     Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., Journal of Drug Targeting, 1992, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., Antiviral Research, 1992, 18, 259-265). 
     Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. S.T.P.Pharma. Sci., 1994, 4, 6, 466). 
     Liposomes also include &#34;sterically stabilized&#34; liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G M1 , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., FEBS Letters, 1987, 223, 42; Wu et al., Cancer Research, 1993, 53, 3765). 
     Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (Ann. N.Y. Acad. Sci., 1987, 507, 64) reported the ability of monosialoganglioside G M1 , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (Proc. Natl. Acad. Sci. U.S.A., 1988, 85, 6949). U.S. Pat. No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G M1  or a galactocerebroside sulfate ester. U.S. Pat. No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.). 
     Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (Bull. Chem. Soc. Jpn., 1980, 53, 2778) described liposomes comprising a nonionic detergent, 2C 12  15G, that contains a PEG moiety. Illum et al. (FEBS Lett., 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Pat. Nos. 4,426,330 and 4,534,899). Klibanov et al. (FEBS Lett., 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (Biochimica et Biophysica Acta, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Pat. Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Pat. No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Pat. No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Pat. Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces. 
     A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Pat. No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Pat. No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene. 
     Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin. 
     Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the &#34;head&#34;) provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285). 
     If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class. 
     If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps. 
     If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class. 
     If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides. 
     The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in Pharmaceutical Dosage Forms, Marcel Dekker, Inc., New York, N.Y., 1988, p. 285). 
     Penetration Enhancers 
     In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs. 
     Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail. 
     Surfactants: In connection with the present invention, surfactants (or &#34;surface-active agents&#34;) are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., J. Pharm. Pharmacol., 1988, 40, 252). 
     Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C 1-10  alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, p.92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654). 
     Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman &amp; Gilman&#39;s The Pharmacological Basis of Therapeutics, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term &#34;bile salts&#34; includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucholic acid (sodium glucholate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Swinyard, Chapter 39 In: Remington&#39;s Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990, pages 782-783; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Yamamoto et al., J. Pharm. Exp. Ther., 1992, 263, 25; Yamashita et al., J. Pharm. Sci., 1990, 79, 579-583). 
     Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, J. Chromatogr., 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines)(Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; Buur et al., J. Control Rel., 1990, 14, 43-51). 
     Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., J. Pharm. Pharmacol., 1987, 39, 621-626). 
     Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Pat. No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides. 
     Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone. 
     Carriers 
     Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, &#34;carrier compound&#34; or &#34;carrier&#34; can refer to a nucleic acid, or analog thereof, which is inert (i.e., does not possess biological activity per se) but is recognized as a nucleic acid by in vivo processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4&#39;isothiocyano-stilbene-2,2&#39;-disulfonic acid (Miyao et al., Antisense Res. Dev., 1995, 5, 115-121; Takakura et al., Antisense &amp; Nucl. Acid Drug Dev., 1996, 6, 177-183). 
     Excipients 
     In contrast to a carrier compound, a &#34;pharmaceutical carrier&#34; or &#34;excipient&#34; is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.). 
     Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like. 
     Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, nonaqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used. 
     Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like. 
     Other Components 
     The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation. 
     Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers. 
     Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include, but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed., Berkow et al., eds., 1987, Rahway, N. J., pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, The Merck Manual of Diagnosis and Therapy, 15th Ed., Berkow et al., eds., 1987, Rahway, N. J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially. 
     In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially. 
     The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC 50  s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years. 
     While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same. 
    
    
     EXAMPLES 
     Example 1 
     Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2&#39;-Alkoxy Amidites 
     2&#39;-Deoxy and 2&#39;-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham Mass. or Glen Research, Inc. Sterling Va.). Other 2&#39;-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Pat. No. 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2&#39;-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360 seconds. 
     Oligonucleotides containing 5-methyl-2&#39;-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., Nucleic Acids Research, 1993, 21, 3197-3203] using commercially available phosphoramidites (Glen Research, Sterling Va. or ChemGenes, Needham Mass.). 
     2&#39;-Fluoro Amidites 
     2&#39;-Fluorodeoxyadenosine Amidites 
     2&#39;-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., J. Med. Chem., 1993, 36, 831-841] and U.S. Pat. No. 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2&#39;-deoxy-2&#39;-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and by modifying literature procedures whereby the 2&#39;-alpha-fluoro atom is introduced by a S N  2-displacement of a 2&#39;-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3&#39;,5&#39;-ditetrahydropyranyl (THP) intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5&#39;-dimethoxytrityl-(DMT) and 5&#39;-DMT-3&#39;-phosphoramidite intermediates. 
     2&#39;-Fluorodeoxyguanosine 
     The synthesis of 2&#39;-deoxy-2&#39;-fluoroguanosine was accomplished using tetraisopropyldisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5&#39;-DMT- and 5&#39;-DMT-3&#39;-phosphoramidites. 
     2&#39;-Fluorouridine 
     Synthesis of 2&#39;-deoxy-2&#39;-fluorouridine was accomplished by the modification of a literature procedure in which 2,2&#39;-anhydro-l-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5&#39;-DMT and 5&#39;-DMT-3&#39;phosphoramidites. 
     2&#39;-Fluorodeoxycytidine 
     2&#39;-deoxy-2&#39;-fluorocytidine was synthesized via amination of 2&#39;-deoxy-2&#39;-fluorouridine, followed by selective protection to give N4-benzoyl-2&#39;-deoxy-2&#39;-fluorocytidine. Standard procedures were used to obtain the 5&#39;-DMT and 5&#39;-DMT-3&#39;phosphoramidites. 
     2&#39;-O-(2-Methoxyethyl) Modified Amidites 
     2&#39;-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., Helvetica Chimica Acta, 1995, 78, 486-504. 
     2,2&#39;-Anhydro[1-(beta-D-arabinofuranosyl)-5-Methyluridine] 
     5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenyl-carbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g, 0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was decanted and the gum was dried in a vacuum oven (60° C. at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4° C.). 
     2&#39;-O-Methoxyethyl-5-Methyluridine 
     2,2&#39;-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160° C. After heating for 48 hours at 155-160° C., the vessel was opened and the solution evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH 3  CN (600 mL) and evaporated. A silica gel column (3 kg) was packed in CH 2  Cl 2  /acetone/MeOH (20:5:3) containing 0.5% Et 3  NH. The residue was dissolved in CH 2  Cl 2  (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of product. Additional material was obtained by reworking impure fractions. 
     2&#39;-O-Methoxyethyl-5&#39;-O-dimethoxytrityl-5-Methyluridine 
     2&#39;-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH 3  CN (200 mL). The residue was dissolved in CHCl 3  (1.5 L) and extracted with 2×500 mL of saturated NaHCO 3  and 2×•mL of saturated NaCl. The organic phase was dried over Na 2  SO 4 , filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et 3  NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%). 
     3&#39;-O-Acetyl-2&#39;-O-methoxyethyl-5&#39;-O-dimethoxytrityl-5-Methyluridine 
     2&#39;-O-Methoxyethyl-5&#39;-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged by TLC, MeOH (50 mL) was added and the mixture evaporated at 35° C. The residue was dissolved in CHCl 3  (800 mL) and extracted with 2×200 mL of saturated sodium bicarbonate and 2×200 mL of saturated NaCl. The water layers were back extracted with 200 mL of CHCl 3 . The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%). An additional 1.5 g was recovered from later fractions. 
     3&#39;-O-Acetyl-2&#39;-O-methoxyethyl-5&#39;-O-dimethoxytrityl-5-methyl-4-triazoleuridine 
     A first solution was prepared by dissolving 3&#39;-O-acetyl-2&#39;-O-methoxyethyl-5&#39;-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH 3  CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1:3 M) in CH 3  CN (1 L), cooled to -5° C. and stirred for 0.5 h using an overhead stirrer. POCl 3  was added dropwise, over a 30 minute period, to the stirred solution maintained at 0-10° C., and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1×300 mL of NaHCO 3  and 2×300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated with EtOAc to give the title compound. 
     2&#39;-O-Methoxyethyl-5&#39;-O-dimethoxytrityl-5-methylcytidine 
     A solution of 3&#39;-O-acetyl-2&#39;-O-methoxyethyl-5&#39;-O-dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH 4  OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2×200 mL). The residue was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH 3  gas was added and the vessel heated to 100° C. for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound. 
     N4-Benzoyl-2&#39;-O-methoxyethyl-5&#39;-O-dimethoxytrityl-5-Methylcytidine 
     2&#39;-O-Methoxyethyl-5&#39;-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl 3  (700 mL) and extracted with saturated NaHCO 3  (2×300 mL) and saturated NaCl (2×300 mL), dried over MgSO 4  and evaporated to give a residue (96 g). The residue was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5% Et 3  NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound. 
     N4-Benzoyl-2&#39;-O-methoxyethyl-5&#39;-O-dimethoxytrityl-5-Methylcytidine-3&#39;-Amidite 
     N4-Benzoyl-2&#39;-O-methoxyethyl-5&#39;-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH 2  Cl 2  (1 L). Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-(isopropyl)phosphite (40.5 mL, 0.123 M) were added with stirring, under a nitrogen atmosphere. The resulting mixture was stirred for 20 hours at room temperature (TLC showed the reaction to be 95% complete). The reaction mixture was extracted with saturated NaHCO 3  (1×300 mL) and saturated NaCl (3×300 mL). The aqueous washes were back-extracted with CH 2  Cl 2  (300 mL), and the extracts were combined, dried over MgSO 4  and concentrated. The residue obtained was chromatographed on a 1.5 kg silica column using EtOAc/hexane (3:1) as the eluting solvent. The pure fractions were combined to give 90.6 g (87%) of the title compound. 
     2&#39;-O-(Aminooxyethyl) Nucleoside Amidites and 2&#39;-O-(dimethylaminooxyethyl) Nucleoside Amidites 
     2&#39;-(Dimethylaminooxyethoxy) Nucleoside Amidites 
     2&#39;-(Dimethylaminooxyethoxy) nucleoside amidites [also known in the art as 2&#39;-O-(dimethylaminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine. 
     5&#39;-O-tert-Butyldiphenylsilyl-O 2  -2&#39;-Anhydro-5-Methyluridine 
     O 2  -2&#39;-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0 g, 0.416 mmol), dimethylaminopyridine (0.66 g, 0.013 eq, 0.0054 mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8 g, 119.0 mL, 1.1 eq, 0.458 mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2×1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600 mL) and the solution was cooled to -10° C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3×200 mL) and dried (40° C., 1 mm Hg, 24 h) to 149 g (74.8%) of white solid. TLC and NMR were consistent with pure product. 
     5&#39;-O-tert-Butyldiphenylsilyl-2&#39;-O-(2-hydroxyethyl)-5-Methyluridine 
     In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5&#39;-O-tert-Butyldiphenylsilyl-O 2  -2&#39;-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160° C. was reached and then maintained for 16 h (pressure&lt;100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1 mm Hg) in a warm water bath (40-100° C.) with the more extreme conditions used to remove the ethylene glycol. [Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2 kg silica gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84 g, 50%), contaminated starting material (17.4 g) and pure reusable starting material 20 g. The yield based on starting material less pure recovered starting material was 58%. TLC and NMR were consistent with 99% pure product. 
     2&#39;-O-([2-phthalimidoxy)ethyl]-5&#39;-t-butyldiphenylsilyl-5-Methyluridine 
     5&#39;-O-tert-Butyldiphenylsilyl-2&#39;-O-(2-hydroxyethyl)-5-methyluridine (20 g, 36.98 mmol) was mixed with triphenylphosphine (11.63 g, 44.36 mmol) and N-hydroxyphthalimide (7.24 g, 44.36 mmol). It was then dried over P 2  O 5  under high vacuum for two days at 40° C. The reaction mixture was flushed with argon and dry THF (369.8 mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98 mL, 44.36 mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and eluted with ethyl acetate:hexane (60:40), to get 2&#39;-O-([2-phthalimidoxy)ethyl]-5&#39;-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%). 
     5&#39;-O-tert-butyldiphenylsilyl-2&#39;-O-[(2-Formadoximinooxy)ethyl]-5-Methyluridine 
     2&#39;-O-([2-phthalimidoxy)ethyl]-5&#39;-t-butyldiphenylsilyl-5-methyluridine (3.1 g, 4.5 mmol) was dissolved in dry CH 2  Cl 2  (4.5 mL) and methylhydrazine (300 mL, 4.64 mmol) was added dropwise at -10° C. to 0° C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH 2  Cl 2  and the combined organic phase was washed with water, brine and dried over anhydrous Na 2  SO 4 . The solution was concentrated to get 2&#39;-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5 mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was strirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5&#39;-O-tert-butyldiphenylsilyl-2&#39;-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%). 
     5&#39;-O-tert-Butyldiphenylsilyl-2&#39;-O-[N,N-dimethylaminooxyethyl]-5-Methyluridine 
     5&#39;-O-tert-butyldiphenylsilyl-2&#39;-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77 g, 3.12 mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6 mL). Sodium cyanoborohydride (0.39 g, 6.13 mmol) was added to this solution at 10° C. under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10° C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH 2  Cl 2 ). Aqueous NaHCO 3  solution (5%, 10 mL) was added and extracted with ethyl acetate (2×20 mL). Ethyl acetate phase was dried over anhydrous Na 2  SO 4 , evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6 mL). Formaldehyde (20% w/w, 30 mL, 3.37 mmol) was added and the reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10° C. in an ice bath, sodium cyanoborohydride (0.39 g, 6.13 mmol) was added and reaction mixture stirred at 10° C. for 10 minutes. After 10 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO 3  (25 mL) solution was added and extracted with ethyl acetate (2×25 mL). Ethyl acetate layer was dried over anhydrous Na 2  SO 4  and evaporated to dryness . The residue obtained was purified by flash column chromatography and eluted with 5% MeOH in CH 2  Cl 2  to get 5&#39;-O-tert-butyldiphenylsilyl-2&#39;-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6 g, 80%). 
     2&#39;-O-(dimethylaminooxyethyl)-5-Methyluridine 
     Triethylamine trihydrofluoride (3.91 mL, 24.0 mmol) was dissolved in dry THF and triethylamine (1.67 mL, 12 mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5&#39;-O-tert-butyldiphenylsilyl-2&#39;-O-[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40 g, 2.4 mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH 2  Cl 2 ). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH 2  Cl 2  to get 2&#39;-O-(dimethylaminooxyethyl)-5-methyluridine (766 mg, 92.5%). 
     5&#39;-O-DMT-2&#39;-O-(dimethylaminooxyethyl)-5-Methyluridine 
     2&#39;-O-(dimethylaminooxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P 2  O 5  under high vacuum overnight at 40° C. It was then co-evaporated with anhydrous pyridine (20 mL). The residue obtained was dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol), 4,4&#39;-dimethoxytrityl chloride (880 mg, 2.60 mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH 2  Cl 2  (containing a few drops of pyridine) to get 5&#39;-O-DMT-2&#39;-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13 g, 80%). 
     5&#39;-O-DMT-2&#39;-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3&#39;-[(2-cyanoethyl)--N,N-diisopropylphosphoramidite] 
     5&#39;-O-DMT-2&#39;-O-(dimethylaminooxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL). To the residue N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and dried over P 2  O 5  under high vacuum overnight at 40° C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N 1 ,N 1  -tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70 mL) and washed with 5% aqueous NaHCO 3  (40 mL). Ethyl acetate layer was dried over anhydrous Na 2  SO 4  and concentrated. Residue obtained was chromatographed (ethyl acetate as eluent) to get 5&#39;-O-DMT-2&#39;-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3&#39;-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04 g, 74.9%). 
     2&#39;-(Aminooxyethoxy) Nucleoside Amidites 
     2&#39;-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2&#39;-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly. 
     N2-isobutyryl-6-O-diphenylcarbamoyl-2&#39;-O-(2-ethylacetyl)-5&#39;-O-(4,4&#39;-dimethoxytrityl) Guanosine-3&#39;-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] 
     The 2&#39;-O-aminooxyethyl guanosine analog may be obtained by selective 2&#39;-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2&#39;-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3&#39;-O-isomer. 2&#39;-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2&#39;-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinosso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2&#39;-O-(2-ethylacetyl)-5&#39;-O-(4,4&#39;-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2&#39;-O-(2-ethylacetyl)-5&#39;-O-(4,4&#39;-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2&#39;-O-(2-ethylacetyl)-5&#39;-O-(4,4&#39;-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2&#39;-O-(2-ethylacetyl)-5&#39;-O-(4,4&#39;-dimethoxytrityl)guanosine-3&#39;-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]. 
     Example 2 
     Oligonucleotide Synthesis 
     Unsubstituted and substituted phosphodiester (P═O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 380B) using standard phosphoramidite chemistry with oxidation by iodine. 
     Phosphorothioates (P═S) are synthesized as for the phosphodiester oligonucleotides except the standard oxidation bottle was replaced by 0.2 M solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the stepwise thiation of the phosphite linkages. The thiation wait step was increased to 68 sec and was followed by the capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55° C. (18 h), the oligonucleotides were purified by precipitating twice with 2.5 volumes of ethanol from a 0.5 M NaCl solution. 
     Phosphinate oligonucleotides are prepared as described in U.S. Pat. No. 5,508,270, herein incorporated by reference. 
     Alkyl phosphonate oligonucleotides are prepared as described in U.S. Pat. No. 4,469,863, herein incorporated by reference. 
     3&#39;-Deoxy-3&#39;-methylene phosphonate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,610,289 or 5,625,050, herein incorporated by reference. 
     Phosphoramidite oligonucleotides are prepared as described in U.S. Pat. No. 5,256,775 or U.S. Pat. No. 5,366,878, herein incorporated by reference. 
     Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference. 
     3&#39;-Deoxy-3&#39;-amino phosphoramidate oligonucleotides are prepared as described in U.S. Pat. No. 5,476,925, herein incorporated by reference. 
     Phosphotriester oligonucleotides are prepared as described in U.S. Pat. No. 5,023,243, herein incorporated by reference. 
     Borano phosphate oligonucleotides are prepared as described in U.S. Pat. Nos. 5,130,302 and 5,177,198, both herein incorporated by reference. 
     Example 3 
     Oligonucleoside Synthesis 
     Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P═O or P═S linkages are prepared as described in U.S. Pat. Nos. 5,378,825, 5,386,023, 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference. 
     Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Pat. Nos. 5,264,562 and 5,264,564, herein incorporated by reference. 
     Ethylene oxide linked oligonucleosides are prepared as described in U.S. Pat. No. 5,223,618, herein incorporated by reference. 
     Example 4 
     PNA Synthesis 
     Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, Bioorganic &amp; Medicinal Chemistry, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Pat. Nos. 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference. 
     Example 5 
     Synthesis of Chimeric Oligonucleotides 
     Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the &#34;gap&#34; segment of linked nucleosides is positioned between 5&#39; and 3&#39; &#34;wing&#34; segments of linked nucleosides and a second &#34;open end&#34; type wherein the &#34;gap&#34; segment is located at either the 3&#39; or the 5&#39; terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as &#34;gapmers&#34; or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as &#34;hemimers&#34; or &#34;wingmers&#34;. 
     [2&#39;-O-Me]--[2&#39;-deoxy]--[2&#39;-O-Me] Chimeric Phosphorothioate Oligonucleotides 
     Chimeric oligonucleotides having 2&#39;-O-alkyl phosphorothioate and 2&#39;-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated synthesizer and 2&#39;-deoxy-5&#39;-dimethoxytrityl-3&#39;-O-phosphoramidite for the DNA portion and 5&#39;-dimethoxytrityl-2&#39;-O-methyl-3&#39;-O-phosphoramidite for 5&#39; and 3&#39; wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s repeated four times for RNA and twice for 2&#39;-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2&#39; positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry. 
     [2&#39;-O-(2-Methoxyethyl)]--[2&#39;-deoxy]--[2&#39;-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides 
     [2&#39;-O-(2-methoxyethyl)]--[2&#39;-deoxy]--[-2&#39;-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2&#39;-O-methyl chimeric oligonucleotide, with the substitution of 2&#39;-O-(methoxyethyl) amidites for the 2&#39;-O-methyl amidites. 
     [2&#39;-O-(2-Methoxyethyl)Phosphodiester]--[2&#39;-deoxy Phosphorothioate]--[2&#39;-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides 
     [2&#39;-O-(2-methoxyethyl phosphodiester]--[2&#39;-deoxy phosphorothioate]--[2&#39;-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2&#39;-O-methyl chimeric oligonucleotide with the substitution of 2&#39;-O-(methoxyethyl) amidites for the 2&#39;-O-methyl amidites, oxidization with iodine to generate the phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3, H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap. 
     Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to U.S. Pat. No. 5,623,065, herein incorporated by reference. 
     Example 6 
     Oligonucleotide Isolation 
     After cleavage from the controlled pore glass column (Applied Biosystems) and deblocking in concentrated ammonium hydroxide at 55° C. for 18 hours, the oligonucleotides or oligonucleosides are purified by precipitation twice out of 0.5 M NaCl with 2.5 volumes ethanol. Synthesized oligonucleotides were analyzed by polyacrylamide gel electrophoresis on denaturing gels and judged to be at least 85% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in synthesis were periodically checked by  31  P nuclear magnetic resonance spectroscopy, and for some studies oligonucleotides were purified by HPLC, as described by Chiang et al., J. Biol. Chem. 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material. 
     Example 7 
     Oligonucleotide Synthesis--96 Well Plate Format 
     Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,H-1,2 benzodithiole-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, Calif., or Pharmacia, Piscataway, N.J.). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected betacyanoethyldiisopropyl phosphoramidites. 
     Oligonucleotides were cleaved from support and deprotected with concentrated NH 4  OH at elevated temperature (55-60° C.) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors. 
     Example 8 
     Oligonucleotide Analysis--96 Well Plate Format 
     The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length. 
     Example 9 
     Cell Culture and Oligonucleotide Treatment 
     The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following four cell types are provided for illustrative purposes, but other cell types can be routinely used. 
     T-24 Cells: 
     The transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). T-24 cells were routinely cultured in complete McCoy&#39;s 5A basal media (Gibco/Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, Md.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis. 
     For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide. 
     A549 Cells: 
     The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, Va.). A549 cells were routinely cultured in DMEM basal media (Gibco/Life Technologies, Gaithersburg, Md.) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, Md.), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, Md.). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. 
     NHDF Cells: 
     Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville Md.). NHDFs were routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville Md. supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier. 
     HEK Cells: 
     Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville Md. HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville Md. formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier. 
     Treatment with Antisense Compounds: 
     When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 μL OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130 μL of OPTI-MEM™-1 containing 3.75 μg/mL LIPOFECTIN™ (Gibco BRL) and the desired oligonucleotide at a final concentration of 150 nM. After 4 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16 hours after oligonucleotide treatment. 
     Example 10 
     Analysis of Oligonucleotide Inhibition of Smad2 Expression 
     Antisense modulation of Smad2 expression can be assayed in a variety of ways known in the art. For example, Smad2 mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley &amp; Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.2.1-4.2.9, John Wiley &amp; Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, Calif. and used according to manufacturer&#39;s instructions. Other methods of PCR are also known in the art. 
     Smad2 protein levels can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to Smad2 can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, Mich.), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.12.1-11.12.9, John Wiley &amp; Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.4.1-11.11.5, John Wiley &amp; Sons, Inc., 1997. 
     Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.16.1-10.16.11, John Wiley &amp; Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 10.8.1-10.8.21, John Wiley &amp; Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 2, pp. 11.2.1-11.2.22, John Wiley &amp; Sons, Inc., 1991. 
     Example 11 
     Poly(A)+mRNA isolation 
     Poly(A)+mRNA was isolated according to Miura et al., Clin. Chem., 1996, 42, 1758-1764. Other methods for poly(A)+mRNA isolation are taught in, for example, Ausubel, F. M. et al., Current Protocols in Molecular Biology, Volume 1, pp. 4.5.1-4.5.3, John Wiley &amp; Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μL cold PBS. 60 μL lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μL of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine Calif.). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μL of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μL of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70° C. was added to each well, the plate was incubated on a 90° C. hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate. 
     Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions. 
     Example 12 
     Total RNA Isolation 
     Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia Calif.) following the manufacturer&#39;s recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μL cold PBS. 100 μL Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μL of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY  96  ™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 μL water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 μL water. 
     Example 13 
     Real-time Quantitative PCR Analysis of Smad2 mRNA Levels 
     Quantitation of Smad2 mRNA levels was determined by real-time quantitative PCR using the ABI PRISM™ 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, Calif.) according to manufacturer&#39;s instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain reaction (PCR) products in real-time. As opposed to standard PCR, in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., JOE or FAM, obtained from either Operon Technologies Inc., Alameda, Calif. or PE-Applied Biosystems, Foster City, Calif.) is attached to the 5&#39; end of the probe and a quencher dye (e.g., TAMRA, obtained from either Operon Technologies Inc., Alameda, Calif. or PE-Applied Biosystems, Foster City, Calif.) is attached to the 3&#39; end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3&#39; quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5&#39;-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular (six-second) intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples. PCR reagents were obtained from PE-Applied Biosystems, Foster City, Calif. RT-PCR reactions were carried out by adding 25 μL PCR cocktail (1×TAQMAN™ buffer A, 5.5 mM MgCl 2 , 300 μM each of dATP, dCTP and dGTP, 600 μM of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNAse inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 μL poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48° C. Following a 10 minute incubation at 95° C. to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95° C. for 15 seconds (denaturation) followed by 60° C. for 1.5 minutes (annealing/extension). Smad2 probes and primers were designed to hybridize to the human Smad2 sequence, using published sequence information (GenBank accession number AF027964, incorporated herein as SEQ ID NO: 1). 
     For Smad2 the PCR primers were: forward primer: GGCTTGCTGCCTTTGGTAAG (SEQ ID NO: 2) reverse primer: TCCATCCCAGCAGTCTCTTCA (SEQ ID NO: 3) and the PCR probe was: FAM-CATGTCGTCCATCTTGCCATTCACG-TAMRA (SEQ ID NO: 4) where FAM (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye. 
     For GAPDH the PCR primers were: forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 5) reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 6)and the PCR probe was: 5&#39; JOE-CAAGCTTCCCGTTCTCAGCC-TAMRA 3&#39; (SEQ ID NO: 7) where JOE (PE-Applied Biosystems, Foster City, Calif.) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, Calif.) is the quencher dye. 
     Example 14 
     Northern Blot Analysis of Smad2 mRNA Levels 
     Eighteen hours after antisense treatment, cell monolayers were washed twice with cold PBS and lysed in 1 mL RNAZOL™ (TEL-TEST &#34;B&#34; Inc., Friendswood, Tex.). Total RNA was prepared following manufacturer&#39;s recommended protocols. Twenty micrograms of total RNA was fractionated by electrophoresis through 1.2% agarose gels containing 1.1% formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon, Ohio). RNA was transferred from the gel to HYBOND™-N+nylon membranes (Amersham Pharmacia Biotech, Piscataway, N.J.) by overnight capillary transfer using a Northern/Southern Transfer buffer system (TEL-TEST &#34;B&#34; Inc., Friendswood, Tex.). RNA transfer was confirmed by UV visualization. Membranes were fixed by UV cross-linking using a STRATALINKER™ UV Crosslinker 2400 (Stratagene, Inc, La Jolla, Calif.). 
     Membranes were probed using QUICKHYB™ hybridization solution (Stratagene, La Jolla, Calif.) using manufacturer&#39;s recommendations for stringent conditions with a Smad2 specific probe prepared by PCR using the forward primer GGCTTGCTGCCTTTGGTAAG (SEQ ID NO: 2) and the reverse primer TCCATCCCAGCAGTCTCTTCA (SEQ ID NO: 3). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, Calif.). Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, Calif.). Data was normalized to GAPDH levels in untreated controls. 
     Example 15 
     Antisense Inhibition of Smad2 Expression-phosphorothioate Oligodeoxynucleotides 
     In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human Smad2 RNA, using published sequences (GenBank accession number AF027964, incorporated herein as SEQ ID NO: 1). The oligonucleotides are shown in Table 1. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. AF027964), to which the oligonucleotide binds. All compounds in Table 1 are oligodeoxynucleotides with phosphorothioate backbones (internucleoside linkages) throughout. The compounds were analyzed for effect on Smad2 mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments. If present, &#34;N.D.&#34; indicates &#34;no data&#34;. 
     
                       TABLE 1                                                     
______________________________________                                    
Inhibition of Smad2 mRNA levels by phosphorothioate                       
  oligodeoxynucleotides                                                   
                                       % In- SEQ                          
                                 TARGET                          hibi-    
                                                    ID                    
  ISIS#   REGION             SITE      SEQUENCE              tion         
                                                NO.                       
______________________________________                                    
27737 5&#39; UTR  5        agctgcttctccgccgcc                                 
                                     73     8                             
  27738       5&#39; UTR        57        aaacagcctcttgtatcg    71            
                                             9                            
  27739       Coding             113       cgtgaatggcaagatgga    53       
                                                  10                      
  27740       Coding             130       ctcttcacaactggcggc    84       
                                                  11                      
  27741       Coding             146       cttccatcccagcagtct    90       
                                                  12                      
  27742       Coding             173       tgctcctccagacccacc    99       
                                                  13                      
  27743       Coding             185       ctctcctccgcctgctcc    99       
                                                  14                      
  27744       Coding             200       ttcctgcccattctgctc    92       
                                                  15                      
  27745       Coding             215       ctcacaccacttttcttc    90       
                                                  16                      
  27746       Coding             225       tcactgctttctcacacc    92       
                                                  17                      
  27747       Coding             239       cttcaccagacttttcac    85       
                                                  18                      
  27748       Coding             264       ctaatcgtcctgttttct    67       
                                                  19                      
  27749       Coding             291       gagtggtgatggctttct    60       
                                                  20                      
  27750       Coding             303       tattacagttttgagtgg    48       
                                                  21                      
  27751       Coding             317       ggtaacacatttagtatt    52       
                                                  22                      
  27752       Coding             330       aagtgcttggtatggtaa    57       
                                                  23                      
  27753       Coding             420       gagacctggtttgttcag    54       
                                                  24                      
  27754       Coding             450       ttcgatgggatacctgga    1        
                                                  25                      
  27755       Coding             596       tctctgatagtggtaagg    51       
                                                  26                      
  27756       Coding             616       ggcaaaactggtgtctca    74       
                                                  27                      
  27757       Coding             663       gcggaagttctgttagga    57       
                                                  28                      
  27758       Coding             703       ttagtgttttctggaatg    52       
                                                  29                      
  27759       Coding             756       gaggtggcgtttctggaa    71       
                                                  30                      
  27760       Coding             796       tgttggtcacttgtttct    42       
                                                  31                      
  27761       Coding             825       gagagcctgtgtccatac    71       
                                                  32                      
  27762       Coding             854       ggaaagagtagtaggaga    52       
                                                  33                      
  27763       Coding             903       caggttctgagtaagtaa    46       
                                                  34                      
  27764       Coding             955       gtttctccaaccctctga    80       
                                                  35                      
  27765       Coding             995       aaagccatctacagtgag    66       
                                                  36                      
  27766       Coding             1034      taaacctaagcagaacct    63       
                                                  37                      
  27767       Coding             1047      taacattggagagtaaac    46       
                                                  38                      
  27768       Coding             1079      ccttcttgtcatttctac    43       
                                                  39                      
  27769       Coding             1125      aaacttccccacctatgt    82       
                                                  40                      
  27770       Coding             1234      agattacagcctggtgga    43       
                                                  41                      
  27771       Coding             1277      ctgagccagaagagcagc    82       
                                                  42                      
  27772       Coding             1354      caccctttcacaaaactc    85       
                                                  43                      
  27773       Coding             1431      actgtagaggtccattca    58       
                                                  44                      
  27774       3&#39; UTR        1553      aatgctatgacagaagag    24            
                                             45                           
  27775       3&#39; UTR        1583      gatagtaaacagtccata    50            
                                             46                           
  27776       3&#39; UTR        1647      acagattccacaaggtgc    78            
                                             47                           
______________________________________                                    
 
    
     As shown in Table 1, SEQ ID NOs 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46 and 47 demonstrated at least 40% inhibition of Smad2 expression in this assay and are therefore preferred. 
     Example 16 
     Antisense Inhibition of Smad2 Expression-phosphorothioate 2&#39;-MOE Gapmer Oligonucleotides 
     In accordance with the present invention, a second series of oligonucleotides targeted to human Smad2 were synthesized. The oligonucleotide sequences are shown in Table 2. Target sites are indicated by nucleotide numbers, as given in the sequence source reference (Genbank accession no. AF07964), to which the oligonucleotide binds. 
     All compounds in Table 2 are chimeric oligonucleotides (&#34;gapmers&#34;) 18 nucleotides in length, composed of a central &#34;gap&#34; region consisting of ten 2&#39;-deoxynucleotides, which is flanked on both sides (5&#39; and 3&#39; directions) by four-nucleodide &#34;wings&#34;. The wings are composed of 2&#39;-methoxyethyl (2&#39;-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P═S) throughout the oligonucleotide. Cytidine residues in the 2&#39;-MOE wings are 5-methylcytidines. 
     Data were obtained by real-time quantitative PCR as described in other examples herein and are averaged from two experiments. If present, &#34;N.D.&#34; indicates &#34;no data&#34;. 
     
                       TABLE 2                                                     
______________________________________                                    
Inhibition of Smad2 mRNA levels by chimeric phospho- - rothioate oligonucl
eotides having 2&#39;-MOE wings and -  a deoxy gap                            
                                       % In- SEQ                          
                                                     TARGET               
                                                              hibi-       
                                               ID                         
  ISIS#      REGION          SITE       SEQUENCE                  tion    
                                             NO.                          
______________________________________                                    
27777  5&#39; UTR 5       agctgcttctccgccgcc                                  
                                     76    8                              
  27778   5&#39; UTR    57         aaacagcctcttgtatcg       66         9      
                                            27779   Coding    113         
                                           cgtgaatggcaagatgga       87    
                                               10                         
  27780   Coding    130        ctcttcacaactggcggc       82        11      
                                            27781   Coding    146         
                                           cttccatcccagcagtct       74    
                                               12                         
  27782   Coding    173        tgctcctccagacccacc      95        13       
                                            27783   Coding    185         
                                           ctctcctccgcctgctcc       87    
                                               14                         
  27784   Coding    200        ttcctgcccattctgctc       91        15      
                                            27785   Coding    215         
                                           ctcacaccacttttcttc       83    
                                               16                         
  27786   Coding    225        tcactgctttctcacacc      94        17       
                                            27787   Coding    239         
                                           cttcaccagacttttcac       83    
                                               18                         
  27788   Coding    264        ctaatcgtcctgttttct       82        19      
                                            27789   Coding    291         
                                           gagtggtgatggctttct       75    
                                               20                         
  27790   Coding    303        tattacagttttgagtgg       71       21       
                                            27791   Coding    317         
                                           ggtaacacatttagtatt       74    
                                               22                         
  27792   Coding    330        aagtgcttggtatggtaa       59        23      
                                            27793   Coding    420         
                                           gagacctggtttgttcag       71    
                                               24                         
  27794   Coding    450        ttcgatgggatacctgga       85        25      
                                            27795   Coding   596          
                                           tctctgatagtggtaagg       61    
                                               26                         
  27796   Coding    616        ggcaaaactggtgtctca       94        27      
                                            27797   Coding    663         
                                           gcggaagttctgttagga       91    
                                               28                         
  27798   Coding    703        ttagtgttttctggaatg       57        29      
                                            27799   Coding    756         
                                           gaggtggcgtttctggaa       76    
                                               30                         
  27800   Coding    796        tgttggtcacttgtttct       64        31      
                                            27801   Coding    825         
                                           gagagcctgtgtccatac       89    
                                               32                         
  27802   Coding    854        ggaaagagtagtaggaga       72        33      
                                            27803   Coding    903         
                                           caggttctgagtaagtaa       78    
                                               34                         
  27804   Coding    955        gtttctccaaccctctga       82        35      
                                            27805   Coding    995         
                                           aaagccatctacagtgag       85    
                                               36                         
  27806   Coding   1034       taaacctaagcagaacct       76        37       
                                            27807   Coding   1047         
                                           taacattggagagtaaac       55    
                                               38                         
  27808   Coding   1079       ccttcttgtcatttctac       67        39       
                                            27809   Coding   1125         
                                           aaacttccccacctatgt       85    
                                               40                         
  27810   Coding   1234       agattacagcctggtgga       66        41       
                                            27811   Coding   1277         
                                           ctgagccagaagagcagc       68    
                                               42                         
  27812   Coding   1354       caccctttcacaaaactc       72        43       
                                            27813   Coding   1431         
                                           actgtagaggtccattca       62    
                                               44                         
  27814   3&#39; UTR   1553       aatgctatgacagaagag       41        45       
                                            27815   3&#39; UTR   1583         
                                           gatagtaaacagtccata       68    
                                               46                         
  27816   3&#39; UTR   1647       acagattccacaaggtgc       81        47       
______________________________________                                    
 
    
     As shown in Table 2, SEQ ID NOs 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 46, and 47 demonstrated at least 50% inhibition of Smad2 expression in this experiment and are therefore preferred. 
     Example 17 
     Western Blot Analysis of Smad2 Protein Levels 
     Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to Smad2 is used with a radiolabelled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale Calif.). 
     
         __________________________________________________________________________
#             SEQUENCE LISTING                                            
   - -  - - &lt;160&gt; NUMBER OF SEQ ID NOS: 47                                
   - - &lt;210&gt; SEQ ID NO 1                                                  
  &lt;211&gt; LENGTH: 1710                                                      
  &lt;212&gt; TYPE: DNA                                                         
  &lt;213&gt; ORGANISM: Homo sapiens                                            
  &lt;220&gt; FEATURE:                                                          
  &lt;221&gt; NAME/KEY: CDS                                                     
  &lt;222&gt; LOCATION: (107)..(1510)                                           
   - - &lt;400&gt; SEQUENCE: 1                                                  
   - - ccgcggcggc ggagaagcag ctcgccagcc agcagcccgc cagccgccgg ga -        
#ggttcgat     60                                                          
   - - acaagaggct gttttcctag cgtggcttgc tgcctttggt aagaac atg - #tcg tcc  
     115                                                                  
                   - #                  - #               Met Ser - #Ser  
                   - #                  - #                 1             
  - - atc ttg cca ttc acg ccg cca gtt gtg aag ag - #a ctg ctg gga tgg aag 
     163                                                                  
 Ile Leu Pro Phe Thr Pro Pro Val Val Lys Ar - #g Leu Leu Gly Trp Lys      
       5            - #      10            - #      15                    
  - - aag tca gct ggt ggg tct gga gga gca ggc gg - #a gga gag cag aat ggg 
     211                                                                  
 Lys Ser Ala Gly Gly Ser Gly Gly Ala Gly Gl - #y Gly Glu Gln Asn Gly      
  20                 - # 25                 - # 30                 - # 35 
  - - cag gaa gaa aag tgg tgt gag aaa gca gtg aa - #a agt ctg gtg aag aag 
     259                                                                  
 Gln Glu Glu Lys Trp Cys Glu Lys Ala Val Ly - #s Ser Leu Val Lys Lys      
                  40 - #                 45 - #                 50        
  - - cta aag aaa aca gga cga tta gat gag ctt ga - #g aaa gcc atc acc act 
     307                                                                  
 Leu Lys Lys Thr Gly Arg Leu Asp Glu Leu Gl - #u Lys Ala Ile Thr Thr      
              55     - #             60     - #             65            
  - - caa aac tgt aat act aaa tgt gtt acc ata cc - #a agc act tgc tct gaa 
     355                                                                  
 Gln Asn Cys Asn Thr Lys Cys Val Thr Ile Pr - #o Ser Thr Cys Ser Glu      
          70         - #         75         - #         80                
  - - att tgg gga ctg agt aca cca aat acg ata ga - #t cag tgg gat aca aca 
     403                                                                  
 Ile Trp Gly Leu Ser Thr Pro Asn Thr Ile As - #p Gln Trp Asp Thr Thr      
      85             - #     90             - #     95                    
  - - ggc ctt tac agc ttc tct gaa caa acc agg tc - #t ctt gat ggt cgt ctc 
     451                                                                  
 Gly Leu Tyr Ser Phe Ser Glu Gln Thr Arg Se - #r Leu Asp Gly Arg Leu      
 100                 1 - #05                 1 - #10                 1 -  
#15                                                                       
   - - cag gta tcc cat cga aaa gga ttg cca cat gt - #t ata tat tgc cga    
tta      499                                                              
  Gln Val Ser His Arg Lys Gly Leu Pro His Va - #l Ile Tyr Cys Arg Leu     
                 120  - #               125  - #               130        
  - - tgg cgc tgg cct gat ctt cac agt cat cat ga - #a ctc aag gca att gaa 
     547                                                                  
 Trp Arg Trp Pro Asp Leu His Ser His His Gl - #u Leu Lys Ala Ile Glu      
             135      - #           140      - #           145            
  - - aac tgc gaa tat gct ttt aat ctt aaa aag ga - #t gaa gta tgt gta aac 
     595                                                                  
 Asn Cys Glu Tyr Ala Phe Asn Leu Lys Lys As - #p Glu Val Cys Val Asn      
         150          - #       155          - #       160                
  - - cct tac cac tat cag aga gtt gag aca cca gt - #t ttg cct cca gta tta 
     643                                                                  
 Pro Tyr His Tyr Gln Arg Val Glu Thr Pro Va - #l Leu Pro Pro Val Leu      
     165              - #   170              - #   175                    
  - - gtg ccc cga cac acc gag atc cta aca gaa ct - #t ccg cct ctg gat gac 
     691                                                                  
 Val Pro Arg His Thr Glu Ile Leu Thr Glu Le - #u Pro Pro Leu Asp Asp      
 180                 1 - #85                 1 - #90                 1 -  
#95                                                                       
   - - tat act cac tcc att cca gaa aac act aac tt - #c cca gca gga att    
gag      739                                                              
  Tyr Thr His Ser Ile Pro Glu Asn Thr Asn Ph - #e Pro Ala Gly Ile Glu     
                 200  - #               205  - #               210        
  - - cca cag agt aat tat att cca gaa acg cca cc - #t cct gga tat atc agt 
     787                                                                  
 Pro Gln Ser Asn Tyr Ile Pro Glu Thr Pro Pr - #o Pro Gly Tyr Ile Ser      
             215      - #           220      - #           225            
  - - gaa gat gga gaa aca agt gac caa cag ttg aa - #t caa agt atg gac aca 
     835                                                                  
 Glu Asp Gly Glu Thr Ser Asp Gln Gln Leu As - #n Gln Ser Met Asp Thr      
         230          - #       235          - #       240                
  - - ggc tct cca gca gaa cta tct cct act act ct - #t tcc cct gtt aat cat 
     883                                                                  
 Gly Ser Pro Ala Glu Leu Ser Pro Thr Thr Le - #u Ser Pro Val Asn His      
     245              - #   250              - #   255                    
  - - agc ttg gat tta cag cca gtt act tac tca ga - #a cct gca ttt tgg tgt 
     931                                                                  
 Ser Leu Asp Leu Gln Pro Val Thr Tyr Ser Gl - #u Pro Ala Phe Trp Cys      
 260                 2 - #65                 2 - #70                 2 -  
#75                                                                       
   - - tca ata gca tat tat gaa tta aat cag agg gt - #t gga gaa acc ttc    
cat      979                                                              
  Ser Ile Ala Tyr Tyr Glu Leu Asn Gln Arg Va - #l Gly Glu Thr Phe His     
                 280  - #               285  - #               290        
  - - gca tca cag ccc tca ctc act gta gat ggc tt - #t aca gac cca tca aat 
    1027                                                                  
 Ala Ser Gln Pro Ser Leu Thr Val Asp Gly Ph - #e Thr Asp Pro Ser Asn      
             295      - #           300      - #           305            
  - - tca gag agg ttc tgc tta ggt tta ctc tcc aa - #t gtt aac cga aat gcc 
    1075                                                                  
 Ser Glu Arg Phe Cys Leu Gly Leu Leu Ser As - #n Val Asn Arg Asn Ala      
         310          - #       315          - #       320                
  - - acg gta gaa atg aca aga agg cat ata gga ag - #a gga gtg cgc tta tac 
    1123                                                                  
 Thr Val Glu Met Thr Arg Arg His Ile Gly Ar - #g Gly Val Arg Leu Tyr      
     325              - #   330              - #   335                    
  - - tac ata ggt ggg gaa gtt ttt gct gag tgc ct - #a agt gat agt gca atc 
    1171                                                                  
 Tyr Ile Gly Gly Glu Val Phe Ala Glu Cys Le - #u Ser Asp Ser Ala Ile      
 340                 3 - #45                 3 - #50                 3 -  
#55                                                                       
   - - ttt gtg cag agc ccc aat tgt aat cag aga ta - #t ggc tgg cac cct    
gca     1219                                                              
  Phe Val Gln Ser Pro Asn Cys Asn Gln Arg Ty - #r Gly Trp His Pro Ala     
                 360  - #               365  - #               370        
  - - aca gtg tgt aaa att cca cca ggc tgt aat ct - #g aag atc ttc aac aac 
    1267                                                                  
 Thr Val Cys Lys Ile Pro Pro Gly Cys Asn Le - #u Lys Ile Phe Asn Asn      
             375      - #           380      - #           385            
  - - cag gaa ttt gct gct ctt ctg gct cag tct gt - #t aat cag ggt ttt gaa 
    1315                                                                  
 Gln Glu Phe Ala Ala Leu Leu Ala Gln Ser Va - #l Asn Gln Gly Phe Glu      
         390          - #       395          - #       400                
  - - gcc gtc tat cag cta act aga atg tgc acc at - #a aga atg agt ttt gtg 
    1363                                                                  
 Ala Val Tyr Gln Leu Thr Arg Met Cys Thr Il - #e Arg Met Ser Phe Val      
     405              - #   410              - #   415                    
  - - aaa ggg tgg gga gca gaa tac cga agg cag ac - #g gta aca agt act cct 
    1411                                                                  
 Lys Gly Trp Gly Ala Glu Tyr Arg Arg Gln Th - #r Val Thr Ser Thr Pro      
 420                 4 - #25                 4 - #30                 4 -  
#35                                                                       
   - - tgc tgg att gaa ctt cat ctg aat gga cct ct - #a cag tgg ttg gac    
aaa     1459                                                              
  Cys Trp Ile Glu Leu His Leu Asn Gly Pro Le - #u Gln Trp Leu Asp Lys     
                 440  - #               445  - #               450        
  - - gta tta act cag atg gga tcc cct tca gtg cg - #t tgc tca agc atg tca 
    1507                                                                  
 Val Leu Thr Gln Met Gly Ser Pro Ser Val Ar - #g Cys Ser Ser Met Ser      
             455      - #           460      - #           465            
  - - taa agcttcacca atcaagtccc atgaaaagac ttaatgtaac aactcttct - #g      
    1560                                                                  
  - - tcatagcatt gtgtgtggtc cctatggact gtttactatc caaaagttca ag -         
#agagaaaa   1620                                                          
   - - cagcacttga ggtctcatca attaaagcac cttgtggaat ctgtttccta ta -        
#tttgaata   1680                                                          
   - - ttagatggga aaattagtgt cataaagatc         - #                  - #  
       1710                                                               
  - -  - - &lt;210&gt; SEQ ID NO 2                                              
 &lt;211&gt; LENGTH: 20                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: PCR Primer                                      
  - - &lt;400&gt; SEQUENCE: 2                                                   
  - - ggcttgctgc ctttggtaag            - #                  - #           
       - # 20                                                             
  - -  - - &lt;210&gt; SEQ ID NO 3                                              
 &lt;211&gt; LENGTH: 21                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: PCR Primer                                      
  - - &lt;400&gt; SEQUENCE: 3                                                   
  - - tccatcccag cagtctcttc a           - #                  - #          
        - #21                                                             
  - -  - - &lt;210&gt; SEQ ID NO 4                                              
 &lt;211&gt; LENGTH: 25                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: PCR Probe                                       
  - - &lt;400&gt; SEQUENCE: 4                                                   
  - - catgtcgtcc atcttgccat tcacg          - #                  - #       
        25                                                                
  - -  - - &lt;210&gt; SEQ ID NO 5                                              
 &lt;211&gt; LENGTH: 19                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: PCR Primer                                      
  - - &lt;400&gt; SEQUENCE: 5                                                   
  - - gaaggtgaag gtcggagtc             - #                  - #           
       - # 19                                                             
  - -  - - &lt;210&gt; SEQ ID NO 6                                              
 &lt;211&gt; LENGTH: 20                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: PCR Primer                                      
  - - &lt;400&gt; SEQUENCE: 6                                                   
  - - gaagatggtg atgggatttc            - #                  - #           
       - # 20                                                             
  - -  - - &lt;210&gt; SEQ ID NO 7                                              
 &lt;211&gt; LENGTH: 20                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: PCR Probe                                       
  - - &lt;400&gt; SEQUENCE: 7                                                   
  - - caagcttccc gttctcagcc            - #                  - #           
       - # 20                                                             
  - -  - - &lt;210&gt; SEQ ID NO 8                                              
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 8                                                   
  - - agctgcttct ccgccgcc             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 9                                              
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 9                                                   
  - - aaacagcctc ttgtatcg             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 10                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 10                                                  
  - - cgtgaatggc aagatgga             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 11                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 11                                                  
  - - ctcttcacaa ctggcggc             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 12                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 12                                                  
  - - cttccatccc agcagtct             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 13                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 13                                                  
  - - tgctcctcca gacccacc             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 14                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 14                                                  
  - - ctctcctccg cctgctcc             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 15                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 15                                                  
  - - ttcctgccca ttctgctc             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 16                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 16                                                  
  - - ctcacaccac ttttcttc             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 17                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 17                                                  
  - - tcactgcttt ctcacacc             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 18                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 18                                                  
  - - cttcaccaga cttttcac             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 19                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 19                                                  
  - - ctaatcgtcc tgttttct             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 20                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 20                                                  
  - - gagtggtgat ggctttct             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 21                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 21                                                  
  - - tattacagtt ttgagtgg             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 22                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 22                                                  
  - - ggtaacacat ttagtatt             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 23                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 23                                                  
  - - aagtgcttgg tatggtaa             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 24                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 24                                                  
  - - gagacctggt ttgttcag             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 25                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 25                                                  
  - - ttcgatggga tacctgga             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 26                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 26                                                  
  - - tctctgatag tggtaagg             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 27                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 27                                                  
  - - ggcaaaactg gtgtctca             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 28                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 28                                                  
  - - gcggaagttc tgttagga             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 29                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 29                                                  
  - - ttagtgtttt ctggaatg             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 30                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 30                                                  
  - - gaggtggcgt ttctggaa             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 31                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 31                                                  
  - - tgttggtcac ttgtttct             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 32                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 32                                                  
  - - gagagcctgt gtccatac             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 33                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 33                                                  
  - - ggaaagagta gtaggaga             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 34                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 34                                                  
  - - caggttctga gtaagtaa             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 35                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 35                                                  
  - - gtttctccaa ccctctga             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 36                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 36                                                  
  - - aaagccatct acagtgag             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 37                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 37                                                  
  - - taaacctaag cagaacct             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 38                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 38                                                  
  - - taacattgga gagtaaac             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 39                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 39                                                  
  - - ccttcttgtc atttctac             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 40                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 40                                                  
  - - aaacttcccc acctatgt             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 41                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 41                                                  
  - - agattacagc ctggtgga             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 42                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 42                                                  
  - - ctgagccaga agagcagc             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 43                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 43                                                  
  - - caccctttca caaaactc             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 44                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 44                                                  
  - - actgtagagg tccattca             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 45                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 45                                                  
  - - aatgctatga cagaagag             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 46                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 46                                                  
  - - gatagtaaac agtccata             - #                  - #            
      - #  18                                                             
  - -  - - &lt;210&gt; SEQ ID NO 47                                             
 &lt;211&gt; LENGTH: 18                                                         
 &lt;212&gt; TYPE: DNA                                                          
 &lt;213&gt; ORGANISM: Artificial Sequence                                      
 &lt;220&gt; FEATURE:                                                           
 &lt;223&gt; OTHER INFORMATION: Antisense Oligonucleotide                       
  - - &lt;400&gt; SEQUENCE: 47                                                  
  - - acagattcca caaggtgc             - #                  - #            
      - #  18                                                             
__________________________________________________________________________